All In Biotech

NDA 022001 · Novo Nordisk INC

Activella

Estradiol, Norethindrone Acetate · Oral

Last checked: Nov 20, 2026Latest source record: Dec 29, 2006 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2006

Dec 29, 2006

Approved uses

1

Original approval plus efficacy supplements

Registered trials

1,701

351 Phase 3, 176 recruiting

FAERS reports

1,888

1,434 serious, 37 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 29, 2006 Original approval · Type 6 - New Indication (no longer used) ReviewLabelLetter
1 products under this application
  • ACTIVELLA · ESTRADIOL 1MG/0.5MG; NORETHINDRONE ACETATE · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Estradiol" as an intervention, any sponsor and status, largest first.

All 1,701 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • breast cancer282
  • breast cancer female191
  • fatigue96
  • nausea94
  • headache80
  • dizziness75
  • pain69
  • drug ineffective68
  • off label use64
  • feeling abnormal60
  • arthralgia58
  • diarrhoea56

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200427
200569
200681
2007155
200862
2009151
2010158
201142
201238
201345
201435
201563
201664
201740
201856
201964
2020103
202190
2022104
2023119
2024106
2025119
202697

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Activella (Estradiol/Norethindrone Acet)

2024 spending

$113K

Beneficiaries

57

203 claims

Per beneficiary

$1,991

$9.60 per unit

View as table
YearSpending
2020$135,011
2021$135,285
2022$141,956
2023$124,690
2024$113,461

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 6,473 on PubMed

Sponsor: Novo Nordisk

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.